Similar articles

• 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

  Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. Tiihonen J, et al. Lancet. 2009 Aug 22;374(9690):620-7. doi: 10.1016/S0140-6736(09)60742-X. Lancet. 2009. PMID: 19595447
• All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study.

  Tenback D, Pijl B, Smeets H, Os Jv, Harten Pv. Tenback D, et al. J Clin Psychopharmacol. 2012 Feb;32(1):31-5. doi: 10.1097/JCP.0b013e31823f3c43. J Clin Psychopharmacol. 2012. PMID: 22198442
• Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.

  Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB. Baandrup L, et al. J Clin Psychiatry. 2010 Feb;71(2):103-8. doi: 10.4088/JCP.08m04818yel. Epub 2009 Nov 3. J Clin Psychiatry. 2010. PMID: 19895781
• Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.

  Hasnain M, Fredrickson SK, Vieweg WV. Hasnain M, et al. J Psychopharmacol. 2011 Jun;25(6):715-21. doi: 10.1177/0269881110389214. Epub 2010 Dec 17. J Psychopharmacol. 2011. PMID: 21169390 Review.
• World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

  Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ; Section of Pharmacopsychiatry, World Psychiatric Association. Tandon R, et al. Schizophr Res. 2008 Mar;100(1-3):20-38. doi: 10.1016/j.schres.2007.11.033. Epub 2008 Feb 19. Schizophr Res. 2008. PMID: 18243663 Review.